The Medicare Drug Price Negotiation Program represents a transformative shift in how the federal government approaches prescription drug affordability for millions of Americans. Enacted through the Inflation Reduction Act of 2022 (IRA), this groundbreaking initiative empowers the Centers for Medicare & Medicaid Services (CMS) to negotiate directly with pharmaceutical manufacturers on behalf of Medicare beneficiaries, targeting some of the costliest medications in the healthcare system.
Understanding the Medicare Drug Price Negotiation Program
The IRA’s drug pricing provisions were designed with dual objectives: reducing Medicare spending on prescription medications while simultaneously expanding access to essential treatments. By requiring federal negotiation of high-cost drugs covered under Medicare Part D, the program addresses long-standing concerns about pharmaceutical affordability that have burdened seniors and disabled Americans for decades.
What distinguishes this program from previous Medicare coverage policies is the comprehensive coverage requirement embedded in the legislation. When drugs are selected for price negotiation, all Medicare Part D plans must cover every dosage form and strength of these medications once negotiated prices become effective. This mandate eliminates the previous patchwork coverage landscape where beneficiaries faced varying levels of access depending on their specific Part D plan.
Coverage Improvements for the First 10 Negotiated Drugs
Recent analysis examining 2026 Medicare Part D formulary data reveals substantial improvements in medication access following implementation of the IRA’s coverage requirements. The first cohort of 10 drugs selected for negotiation, with Medicare-negotiated prices effective January 1, 2026, now demonstrates universal coverage across all Part D plans.
Dramatic Expansion for Insulin Products and Cancer Medications
The coverage transformation has been particularly striking for certain therapeutic categories. Insulin products Fiasp and NovoLog exemplify the program’s impact on diabetes management. In 2025, before the IRA’s coverage requirement took effect, Fiasp was accessible to only 24% of Part D enrollees, while NovoLog reached just 32% of beneficiaries. Under the new framework, 100% of Medicare Part D enrollees now have guaranteed access to these critical diabetes treatments.
Similarly, Imbruvica, a cancer medication used primarily for blood cancers, has seen remarkable coverage expansion. Two specific dosages that were previously available to approximately half of Part D enrollees in 2025 are now universally covered across all plans. This ensures that Medicare beneficiaries diagnosed with conditions like chronic lymphocytic leukemia or mantle cell lymphoma can access their prescribed treatments without coverage barriers.
Universal Access Across All Selected Medications
Beyond these highlighted examples, nine out of the first 10 drugs selected for negotiation have experienced improved coverage rates for various dosage forms and strengths. The IRA’s comprehensive coverage mandate has effectively eliminated coverage gaps that previously forced beneficiaries to either switch medications, appeal coverage denials, or pay out-of-pocket for non-covered formulations.
Looking Ahead: The Second Round of Negotiated Drugs for 2027
The program’s second phase involves 15 additional drugs selected for price negotiation, with agreed-upon prices scheduled to take effect in 2027. Analysis of current 2026 formulary coverage reveals that several of these medications will see significant access improvements once the coverage requirements apply.
The Wegovy Coverage Challenge and Opportunity
Among the 15 drugs selected for 2027 negotiations, Wegovy presents a unique coverage scenario. This GLP-1 medication, approved for both obesity treatment and cardiovascular disease risk reduction, currently appears on formularies serving less than 1% of Part D enrollees in 2026. The limited coverage stems from Medicare’s statutory prohibition on covering medications prescribed primarily for weight loss.
However, the Trump administration has announced plans for a temporary voluntary model beginning in 2027 that would expand Medicare coverage of GLP-1 medications for obesity treatment. This initiative, combined with the IRA’s coverage requirement for Wegovy as a selected drug, could dramatically increase beneficiary access to this medication for both cardiovascular protection and weight management.
Additional Drugs Gaining Broader Coverage
Six other medications selected for 2027 negotiation currently lack universal coverage but will soon be accessible to all Part D enrollees:
- Austedo and Austedo XR: Treatments for involuntary movement disorders, currently covered for 72% and 51% of enrollees respectively
- Otezla: A psoriasis and psoriatic arthritis treatment available to 68% of current enrollees
- Breo Ellipta: An asthma and COPD medication covered for 74% of beneficiaries
Protected Class Drugs Already Widely Covered
Several drugs in the 2027 negotiation cohort already enjoy near-universal coverage because they belong to Medicare’s six protected drug classes, which require broad formulary inclusion. These include cancer treatments Xtandi, Pomalyst, Ofev, Ibrance, and Calquence (all antineoplastics), plus Vraylar, an antipsychotic medication. For these medications, the negotiated prices will lower costs without significantly changing coverage patterns.
Impact on Medicare Beneficiaries and the Healthcare System
The Medicare Drug Price Negotiation Program represents a fundamental restructuring of pharmaceutical access within the nation’s largest health insurance system. By combining price negotiations with mandatory comprehensive coverage, the IRA addresses both affordability and accessibility challenges that have long plagued Medicare beneficiaries managing chronic and serious conditions.
As negotiated prices take effect and coverage requirements expand, millions of Medicare enrollees will benefit from both lower out-of-pocket costs and guaranteed access to clinically necessary medications across all dosage forms and strengths.
